Hemostatic Disorders
Welcome,         Profile    Billing    Logout  
 195 Companies   327 Products   327 Products   167 Mechanisms of Action   13 Trials   3266 News 


«12345678910111213...6768»
  • ||||||||||  Trial completion date:  ACUFOCIN: Standard Care Alone or With Acupuncture for CIPN in Breast Cancer and Multiple Myeloma (clinicaltrials.gov) -  Dec 3, 2018   
    P2,  N=120, Active, not recruiting, 
    N=300 --> 147 | Trial completion date: Dec 2014 --> Jun 2018 | Recruiting --> Terminated | Trial primary completion date: Apr 2013 --> Jun 2018; Sponsor decision based on portfolio prioritization Trial completion date: May 2019 --> Dec 2018
  • ||||||||||  Phase classification, Trial completion date, Trial termination, Metastases:  Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic Cancer (clinicaltrials.gov) -  Nov 7, 2018   
    P=N/A,  N=11, Terminated, 
    Active, not recruiting --> Completed Phase classification: P2 --> P=N/A | Trial completion date: Aug 2017 --> Apr 2017 | Active, not recruiting --> Terminated; PI left the department; protocol transfer did not take place.
  • ||||||||||  Trial completion, Enrollment change, Trial initiation date, Trial primary completion date, HEOR:  A Progressive Resistance Training Program in Patients With Haemophilia (clinicaltrials.gov) -  Oct 18, 2018   
    P=N/A,  N=20, Completed, 
    N=50 --> 0 | Recruiting --> Withdrawn Not yet recruiting --> Completed | N=35 --> 20 | Initiation date: Jan 2017 --> Oct 2017 | Trial primary completion date: Jan 2018 --> Jun 2018
  • ||||||||||  BeneFix (nonacog alfa) / Pfizer
    Trial completion date:  BeneFIX Drug Use Results Survey [All-Case Surveillance] (clinicaltrials.gov) -  Oct 18, 2018   
    P=N/A,  N=314, Completed, 
    Active, not recruiting --> Completed Trial completion date: Aug 2014 --> Feb 2017
  • ||||||||||  cyclophosphamide / Generic mfg.
    Trial completion, Phase classification, Trial completion date, Trial primary completion date, Post-transplantation:  Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide (clinicaltrials.gov) -  Oct 17, 2018   
    P1,  N=127, Completed, 
    Trial completion date: Aug 2014 --> Feb 2017 Active, not recruiting --> Completed | Phase classification: P1/2 --> P1 | Trial completion date: Jun 2022 --> Mar 2018 | Trial primary completion date: Jun 2019 --> Mar 2018
  • ||||||||||  Xyntha (moroctocog alfa) / Pfizer
    Enrollment change, Trial withdrawal:  Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A (clinicaltrials.gov) -  Sep 26, 2018   
    P4,  N=0, Withdrawn, 
    Active, not recruiting --> Completed N=21 --> 0 | Completed --> Withdrawn
  • ||||||||||  Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy:  Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma (clinicaltrials.gov) -  Sep 10, 2018   
    P1,  N=20, Completed, 
    Recruiting --> Completed | N=50 --> 30 N=15 --> 20 | Trial completion date: Jun 2018 --> Jul 2016 | Trial primary completion date: Apr 2018 --> Apr 2016 | Active, not recruiting --> Completed
  • ||||||||||  ATryn (antithrombin) / LFB Biotechnologies, Knight Therap
    Enrollment change, Trial withdrawal:  Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients (clinicaltrials.gov) -  Sep 10, 2018   
    P1,  N=0, Withdrawn, 
    N=15 --> 20 | Trial completion date: Jun 2018 --> Jul 2016 | Trial primary completion date: Apr 2018 --> Apr 2016 | Active, not recruiting --> Completed N=10 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  decitabine / Generic mfg.
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia (clinicaltrials.gov) -  Aug 21, 2018   
    P2,  N=45, Completed, 
    Trial primary completion date: Dec 2013 --> Mar 2016 Recruiting --> Completed | N=30 --> 45 | Trial completion date: Dec 2017 --> Aug 2018 | Trial primary completion date: Dec 2016 --> Oct 2017
  • ||||||||||  Willfact (human von Willebrand factor) / LFB Biotechnologies
    Trial completion:  Willebrand International Non-interventional Global Surveillance (clinicaltrials.gov) -  Aug 8, 2018   
    P=N/A,  N=80, Completed, 
    N=182 --> 0 | Not yet recruiting --> Withdrawn | Initiation date: Jun 2019 --> Dec 2016 | Trial primary completion date: Aug 2020 --> Dec 2016 Recruiting --> Completed
  • ||||||||||  dexamethasone / Generic mfg., lenalidomide / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Lenalidomide (Revlimid (clinicaltrials.gov) -  Aug 2, 2018   
    P2,  N=67, Completed, 
    Recruiting --> Active, not recruiting | Trial completion date: Oct 2024 --> Oct 2019 | Trial primary completion date: Oct 2021 --> Oct 2019 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jul 2018 | Trial primary completion date: Dec 2018 --> Jul 2018
  • ||||||||||  Trial completion, Trial completion date, Trial initiation date, Trial primary completion date:  Early Administration of Fibrinogen in Polytraumatized Patients With Hypofibrinogenemia: a Randomized Feasibility Trial (clinicaltrials.gov) -  Aug 1, 2018   
    P4,  N=32, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Apr 2018 --> Jul 2018 Recruiting --> Completed | Trial completion date: Dec 2017 --> Jul 2018 | Initiation date: Aug 2014 --> Dec 2015 | Trial primary completion date: Dec 2017 --> Jan 2017
  • ||||||||||  letetresgene autoleucel (GSK3377794) / Adaptimmune
    Enrollment change, Trial completion date, Trial termination:  CT Antigen TCR-Engineered T Cells for Myeloma (clinicaltrials.gov) -  Jul 24, 2018   
    P1/2,  N=6, Terminated, 
    Active, not recruiting --> Completed N=10 --> 6 | Trial completion date: Apr 2031 --> Apr 2018 | Active, not recruiting --> Terminated; Sponsor Decision
  • ||||||||||  Promacta (eltrombopag) / Novartis
    Enrollment change, Trial termination:  End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia (clinicaltrials.gov) -  Jul 17, 2018   
    P=N/A,  N=35, Terminated, 
    N=10 --> 6 | Trial completion date: Apr 2031 --> Apr 2018 | Active, not recruiting --> Terminated; Sponsor Decision N=20 --> 35 | Recruiting --> Terminated
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Enrollment change, Trial termination:  Dex/Rituxan: A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone (clinicaltrials.gov) -  Jul 16, 2018   
    P=N/A,  N=72, Terminated, 
    N=69 --> 26 | Active, not recruiting --> Terminated; Lack of accrual N=50 --> 72 | Recruiting --> Terminated
  • ||||||||||  desmopressin / Generic mfg.
    Trial completion, Enrollment change:  Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers (clinicaltrials.gov) -  Jul 16, 2018   
    P1,  N=2, Completed, 
    N=26 --> 18 | Trial completion date: Jun 2015 --> Jun 2018 | Trial primary completion date: Jun 2015 --> Jun 2018 Enrolling by invitation --> Completed | N=25 --> 2
  • ||||||||||  RiaSTAP (fibrinogen concentrate (human)) / CSL Behring
    Enrollment change, Trial termination:  TOP-CLOT: Trial of RiaSTAP Versus Cryoprecipitate to Lower Operative Transfusions (clinicaltrials.gov) -  Jul 5, 2018   
    P=N/A,  N=19, Terminated, 
    N=76 --> 3 N=133 --> 19 | Recruiting --> Terminated; Feasibility issues prevent completion of recruitment.
  • ||||||||||  Trial completion date, Trial primary completion date:  Study of the Immune Response After Vaccination in Multiple Myeloma Patients (clinicaltrials.gov) -  Jul 2, 2018   
    P=N/A,  N=19, Active, not recruiting, 
    Recruiting --> Completed Trial completion date: Nov 2017 --> Nov 2019 | Trial primary completion date: Nov 2017 --> Nov 2019